Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 301

The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.

Immunological Approaches Towards Cancer and Inflammation: A Cross Talk

Open access
Qu, Xinglong, Tang, Ying, Hua, Shucheng·2018·Frontiers in Immunology

Abstract

The inflammation is the protective response of the body against various harmful stimuli, however, the aberrant and inappropriate activation tends to become harmful. The acute inflammatory response tends to resolved once the offending agent is subside but this acute response becomes chronic in nature when the body is unable to successfully neutralized the noxious stimuli. This chronic inflammatory microenvironment is associated with the release of various pro-inflammatory and oncogenic mediators such as nitric oxide (NO), cytokines (IL-1β, IL-2, IL-6 and TNF-α), growth factor and chemokines. These mediators make the inflammatory microenvironment more vulnerable towards tumorigenesis. The pro-inflammatory mediators released during the chronic inflammation tends to induce several molecular signaling cascades such as NF-κB, MAPKinase, Nrf2, Pi3K, JAK/STAT, Wnt/B-catenin, and CREB. The immune system and its components have a pleiotropic effect on inflammation and cancer progression. Immune components such as T cells, NK cells, macrophages, and neutrophils either inhibit or enhance tumor initiation depending upon the type of tumor and immune cells involved. Tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) are pro-tumorigenic cells highly prevalent in inflammation-mediated tumors. Similarly, presence of T regulatory (Treg) cells in an inflammatory and tumor setting suppresses the immune system, thus paving the way for oncogenesis. However, Treg cells also inhibit autoimmune inflammation. In contrast, cytotoxic T cells and T helper cells confer anti-tumor immunity and are associated with better prognosis in patients with cancer. Cytotoxic T cells inflict a direct cytotoxic effect on cells expressing oncogenic markers. Currently, several anti-inflammatory and anti-tumor therapies are under trials in which these immune cells are exploited. Adoptive cell transfer (ACT) comprised of tumor infiltrating lymphocytes (TILs) has been tried for the treatment of tumors after their ex vivo expansion. Mediators released by cells in a tumorigenic and inflammatory microenvironment cross talk with nearby cells, either promoting or inhibiting inflammation and cancer. Recently, several cytokine-based therapies are either being developed or are under trial to treat such types of manifestations. Monoclonal antibodies directed against TNF-α, VEGF, and IL-6 has shown promising results to ameliorate inflammation and cancer, while direct administration of IL-2 has been shown to cause tumor regression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2018.00563

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 159 references

Cited by

See all 301

Metadata

Authors
Qu, X., Tang, Y., & Hua, S.
Venue
Frontiers in Immunology
Published
2018-03-20
Volume
9
Pages
563-563
ISSN
1664-3224 (ISSN-L)
OpenAlex
W2791966010
Cited by
301
References
159
FWCI
12.99
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunological Approaches Towards Cancer and Inflammation: A Cross Talk. https://app.cochat.ai/papers/10.3389/fimmu.2018.00563
The paper
Qu, X., Tang, Y., & Hua, S. (2018). Immunological Approaches Towards Cancer and Inflammation: A Cross Talk. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.00563

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.